Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges.

摘要: The epidermal growth factor receptor (EGFR) plays a key role in cancer development and progression several human malignancies including non-small cell lung (NSCLC). Several strategies aimed at inhibiting the EGFR have been investigated last years, use of small tyrosine kinase inhibitors (TKIs) directed against intracellular domain monoclonal antibodies targeting its extracellular portion. Subgroups patients who are more likely to respond TKIs identified based on both clincal biological features. Never-smoking history has emerged as most relevant clinical characteristic predictive response NSCLC, while presence drugsensitive mutations gene gain represent critical variables associated with an improved outcome for exposed these agents. Recent studies highlighted existence factors involved intrinsic acquired resistance TKIs, k-ras, HER-2 exon 20 mutations. Increasing knowledge biology drug-receptor interactions will allow identify individuals derive benefit from proposed targeted therapy, sparing refractory expensive potentially toxic treatment.